Biodesix Inc (NAS:BDSX)

Q4 2025 Biodesix Inc Earnings Call Transcript

Feb 26, 2026 / 09:30 PM GMT

Release Date Price: $14.22 (+9.98%)

Transcript 10-K8-K

Key Points

Positve

Biodesix Inc (BDSX) reported a 41% increase in revenue for the fourth quarter of 2025, showcasing strong top-line growth.
The company achieved an impressive gross margin of 83%, a 400 basis point improvement, indicating enhanced operational efficiency.
Biodesix Inc (BDSX) reached adjusted EBITDA positivity for the first time, reflecting strong revenue flow and operational leverage.
The company expanded its sales strategy, resulting in a 67% growth in test volumes from primary care and a 26% increase from pulmonology.
Biodesix Inc (BDSX) announced key partnerships with ThermoFisher Scientific and BioA Laboratories, highlighting the strength of its development services.

Negative

The company anticipates a seasonal step down in average selling price (ASP) and volume in the first quarter of 2026 due to weather disruptions and historical trends.
Despite revenue growth, Biodesix Inc (BDSX) reported a net loss of $4 million for the fourth quarter, although this was an improvement over the previous year.
The company is not planning to commercialize any new tests within the next 12 months, focusing instead on profitability and reimbursement timing.
Biodesix Inc (BDSX) faces challenges in publishing real-world data as it relies on independent physicians to share their findings.
The company is still in the early stages of penetrating the primary care market, with primary care volumes accounting for only 12% of total notified test orders.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

BDSX.OQ - Biodesix Inc
Q4 2025 Biodesix Inc Earnings Call
Feb 26, 2026 / 09:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good day and thank you for standing by. Welcome to the Biodesics 4th quarter 2025 earnings conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press 11 on your telephone. You will then hear an automated message advising your hand is raised to withdraw your question, please press 11 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Chris Brinzy. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
-----------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.